Yossi Ofek, General Manager of Teva Israel and Cluster Head – Israel, Ukraine and S. Africa elaborated “This partnership with Prestige further demonstrates our focus on biopharmaceuticals and ...

A U.S. appeals court has sided with Johnson & Johnson (NYSE:JNJ) in a patent dispute with Viatris (NASDAQ:VTRS) and Teva Pharmaceutical (NYSE:TEVA) over the company’s neurology drug Invega Sustenna.

Teva Pharmaceutical Industries Limited’s share was trading at $17.09 as of June 24th. TEVA’s trailing and forward P/E ratios were 872.00 and 6.53, respectively, according to Yahoo Finance ...